Literature DB >> 35968326

Overexpression of glucocorticoid receptor promotes the poor progression and induces cisplatin resistance through p38 MAP kinase in cervical cancer patients.

Gwan Hee Han1, Hee Yun2, Julie Kim3, Joon-Yong Chung4, Jae-Hoon Kim5,6, Hanbyoul Cho5,6.   

Abstract

Glucocorticoid receptor (GR) is activated by synthetic glucocorticoid or endogenous cortisol which were released by the physical and psychosocial stress, and recent studies reported that it is involved in tumor initiation and metastasis in various solid cancers. However, role of GR in cervical cancer has not been elucidated yet. Therefore, here we aim to unveil the role of GR in cervical cancer with cervical cancer clinical specimen and cervical cancer cell lines. We found that overexpression of GR was associated with poor prognosis in cervical cancer patients. Also, GR knockdown in cervical cancer cell lines showed diminished proliferation, invasion and EMT properties. Besides, we found that GR was positively associated with FoxP3 expression, and combination of GR and FoxP3 overexpression revealed as more reliable biomarker for poor prognosis and poor response to chemotherapy of cervical cancer patient than GR alone. Moreover, FACS-based Annexin-V/PI double staining and cleavage of poly ADP ribose polymerase (PARP) showed that siGR enhanced cisplatin-induced apoptosis, which was mediated by p38 MAP kinase. Collectively, our findings established that the combination of high GR and FoxP3 was associated with cervical cancer progression and platinum resistance, suggesting a potential predictive biomarker for clinical management in patients with cervical cancer. AJCR
Copyright © 2022.

Entities:  

Keywords:  FoxP3; Glucocorticoid receptor; biomarker; cervical cancer; cisplatin resistance

Year:  2022        PMID: 35968326      PMCID: PMC9360232     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  43 in total

1.  Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors.

Authors:  Chengwen Zhang; Till Wenger; Jürgen Mattern; Septimia Ilea; Christian Frey; Paul Gutwein; Peter Altevogt; Wolfram Bodenmüller; Nikolaus Gassler; Philipp A Schnabel; Hendrik Dienemann; Alexander Marmé; Markus Hohenfellner; Axel Haferkamp; Jesco Pfitzenmaier; Hermann-Josef Gröne; Armin Kolb; Peter Büchler; Markus Büchler; Helmut Friess; Werner Rittgen; Lutz Edler; Klaus-Michael Debatin; Peter H Krammer; Hans P Rutz; Ingrid Herr
Journal:  Cancer Biol Ther       Date:  2007-02-27       Impact factor: 4.742

2.  Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Authors:  Maxwell N Skor; Erin L Wonder; Masha Kocherginsky; Anju Goyal; Ben A Hall; Yi Cai; Suzanne D Conzen
Journal:  Clin Cancer Res       Date:  2013-09-09       Impact factor: 12.531

3.  The selective impact of transgenically expressed glucocorticoid receptor on T cells.

Authors:  Konstantin Yakimchuk; Liying Chen; Mohammad Sharif Hasni; Sam Okret; Mikael Jondal
Journal:  Autoimmunity       Date:  2014-11-17       Impact factor: 2.815

4.  Glucocorticoids promote breast cancer metastasis.

Authors:  Milan M S Obradović; Baptiste Hamelin; Nenad Manevski; Joana Pinto Couto; Atul Sethi; Marie-May Coissieux; Simone Münst; Ryoko Okamoto; Hubertus Kohler; Alexander Schmidt; Mohamed Bentires-Alj
Journal:  Nature       Date:  2019-03-13       Impact factor: 49.962

5.  Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

Authors:  Ninke Leffers; Marloes J M Gooden; Renske A de Jong; Baukje-Nynke Hoogeboom; Klaske A ten Hoor; Harry Hollema; H Marieke Boezen; Ate G J van der Zee; Toos Daemen; Hans W Nijman
Journal:  Cancer Immunol Immunother       Date:  2008-09-13       Impact factor: 6.968

Review 6.  Human papillomavirus and cervical cancer.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

7.  Glucocorticoid receptor in cervical cancer: an immunhistochemical analysis.

Authors:  Bernd Peter Kost; Susanne Beyer; Lennard Schröder; Junyan Zhou; Doris Mayr; Christina Kuhn; Sandra Schulze; Simone Hofmann; Sven Mahner; Udo Jeschke; Helene Heidegger
Journal:  Arch Gynecol Obstet       Date:  2018-10-10       Impact factor: 2.344

8.  Validation of the 2018 FIGO cervical cancer staging system.

Authors:  Koji Matsuo; Hiroko Machida; Rachel S Mandelbaum; Ikuo Konishi; Mikio Mikami
Journal:  Gynecol Oncol       Date:  2018-10-30       Impact factor: 5.482

9.  Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer.

Authors:  Chengwen Zhang; Armin Kolb; Peter Büchler; Andrew C B Cato; Jürgen Mattern; Werner Rittgen; Lutz Edler; Klaus-Michael Debatin; Markus W Büchler; Helmut Friess; Ingrid Herr
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.